Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F11%3A00053036" target="_blank" >RIV/00216224:14110/11:00053036 - isvavai.cz</a>
Alternative codes found
RIV/65269705:_____/11:#0001241
Result on the web
<a href="http://dx.doi.org/10.1182/blood-2010-12-323980" target="_blank" >http://dx.doi.org/10.1182/blood-2010-12-323980</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1182/blood-2010-12-323980" target="_blank" >10.1182/blood-2010-12-323980</a>
Alternative languages
Result language
angličtina
Original language name
Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia
Original language description
We conducted an international phase 2 trial to evaluate 2 dose levels of ofatumumab, a human CD20 mAb, combined with fludarabine and cyclophosphamide (O-FC) as frontline therapy for chronic lymphocytic leukemia (CLL). Patients with active CLL were randomized to ofatumumab 500 mg (n = 31) or 1000 mg (n = 30) day 1, with fludarabine 25 mg/m2 and cyclophosphamide 250 mg/m2 days 2-4, course 1; days 1-3, courses 2-6; every 4 weeks for 6 courses. The first ofatumumab dose was 300 mg for both cohorts. The median age was 56 years; 13% of patients had a 17p deletion; 64% had B2-microglobulin > 3.5 mg/L. Based on the 1996 National Cancer Institute Working Group (NCI-WG) guidelines, the complete response (CR) rate as assessed by an independent review committeewas 32% for the 500-mg and 50% for the 1000-mg cohort; the overall response (OR) rate was 77% and 73%, respectively.
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2011
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Blood
ISSN
0006-4971
e-ISSN
—
Volume of the periodical
117
Issue of the periodical within the volume
24
Country of publishing house
US - UNITED STATES
Number of pages
9
Pages from-to
6450-6458
UT code for WoS article
000291684300010
EID of the result in the Scopus database
—